AUSTIN, Texas, Sept. 8 /PRNewswire-FirstCall/ — Luminex
Corporation (Nasdaq:
LMNX), today announced that initial results from a study
conducted at the NMI Natural and Medical Sciences Institute at the
University of Tubingen in Germany demonstrate that its MAGPIX®
system provides more cost effective and efficient results than a
conventional microtiter plate based ELISA method.
(Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO)
(Logo: http://www.newscom.com/cgi-bin/prnh/20100104/LUMINEXLOGO)
“These initial results demonstrate why MAGPIX could be a good
choice for every research laboratory,” said Dr. Thomas Joos, the
head of the Biochemistry Department at the Natural and Medical
Sciences Institute. “The system is a great choice for labs seeking
one platform that allows the efficiency of multiplexing as well as
the ability to run single tests, as needed. It can help labs save
resources, increase efficiency and maximize results.”
The NMI Natural and Medical Sciences Institute performed a
comparative study between the recently launched MAGPIX system and a
conventional ELISA method. The study utilized an assay for
soluble tumor necrosis factor receptor II to compare the analytical
methods using several parameters including optimal detection
antibody concentration, dynamic range and assay sensitivity, sample
measurement, intra- and inter-assay precision, parallelism, and
dilution linearity. In addition to analytical performance, a
time and motion analysis, and a cost comparison was performed.
The findings from this initial study demonstrate that MAGPIX
provides accurate assay results at costs of as much as half of the
microtiter plate ELISA method with equivalent sensitivity. While
total
‘/>”/>
SOURCE